More research is essential to improve protocols for diagnosing Alzheimer’s disease in people with Down syndrome, but the ability to identify and care for those patients is enhanced significantly if clinicians are aware of specific circumstances and use a multi-disciplinary treatment strategy. Those findings are included in a study titled …
Researchers report identifying the molecular mechanisms responsible for activating the neuroglobin gene, which scientists think may protect people from developing Alzheimer’s disease. Moreover, the researchers suggest that scientists should explore ways of activating the gene as potential treatments for Alzheimer’s disease. The study, titled “Identification of a novel…
Twenty-five years have passed since researchers launched the idea that Alzheimer’s is a direct result of clumps of amyloid-beta littering the brain. The amyloid hypothesis of Alzheimer’s disease, as it is called, quickly raised hopes among researchers and patients alike that the dreaded disease would soon be under our control. But…
Researchers announced the start of what is being called the largest and most thorough study yet undertaken to identify biomarkers of Alzheimer’s disease before symptoms occur. Such findings could help determine the success of Alzheimer clinical trials and lead to earlier diagnoses. The British effort involves the translational research firm Imanova,…
At the recent Alzheimer’s Association International Conference (AAIC) 2016, held in Toronto, Canada, Muses Labs presented data from a pilot study of its MEND Protocol for treatment of early Alzheimer’s disease. The few drugs available today to slow the progression of Alzheimer’s disease target individual brain factors. Plenty of research,…
ProMIS Neurosciences reported progress of drug discovery technologies at the recent Alzheimer’s Association International Conference (AAIC) meeting, held in Toronto, Canada, showing that the technologies specifically target certain forms of amyloid-beta and tau in Alzheimer’s disease. The company works to identify structures on the surface of the toxic variants of…
Researchers at Genentech discovered that antibodies against tau — a protein creating toxic tangles inside nerve cells of people with Alzheimer’s disease — protect from tau toxicity only when antibodies don’t engage inflammation-triggering microglial cells to get rid of the protein. The findings, published in the journal Cell…
Actinogen Medical announced early clinical study data for Xanamem, a drug designed to lower brain cortisol and intended for the treatment of Alzheimer’s disease, at the Alzheimer’s Association International Conference (AAIC) 2016, held in Toronto, Canada. Xanamem works by blocking excess cortisol production in the hippocampus and frontal cortex, two brain…
Researchers at the Technical University of Madrid, in Spain, have discovered that changes in nerve signaling patterns exist in the brains of people with mild cognitive impairment, a condition believed to precede Alzheimer’s disease and other dementias. From the study ”A multicenter study of the early detection of synaptic…
In mid-July, scientists at the Washington University Medical School, Saint Louis, published a study that inspired awe in fellow researchers — an updated map of the cerebral cortex of the human brain, identifying nearly 100 new areas. The exceedingly intricate and updated map, published in the journal Nature…
Get regular updates to your inbox.